The number is one and it’s loud: 1.5%. It’s the average EBITDA of Italian pharmaceutical intermediate distribution (DIF) in 2024-2025, certified by the Polimi Contract Logistics Healthcare Observatory 2025. For orientation, Italian contract logistics as a whole runs at 5.3%, regional carriers at 4.7%, national carriers at 5.8%. Italian DIF is about one third of the average profitability of the sector it formally belongs to.
The raw number is already eloquent enough, but a second number is needed to understand where the real problem sits: 47% of Italian DIF operators have an EBITDA below 2%. The distribution is not symmetric; nearly half the sector works below the threshold generally considered the frontier of long-term sustainability for an industrial activity with low working capital. The 1.5% average hides, in other words, a concentration of operators in the red zone.
A note for non-Italian readers: this article focuses on a structural anomaly of the Italian pharmaceutical wholesale system, where margin is fixed by law (rather than contractually negotiated as in most other EU markets) and where direct distribution by manufacturers absorbs an unusually high share of the market. The phenomenon and its operational consequences are however quantitative and transferable to any analyst looking at country comparables.
This article addresses three questions that follow. Why is DIF profitability structurally below logistics average? How much does 1.5% EBITDA actually weigh on the P&L of a typical intermediate distributor? And what are the concrete levers that a DIF wholesaler can pull to recover margin points without waiting for macroscopic regulatory interventions?
We do it starting from hard data (Polimi, 2025 Italian Budget Law, TAR Feb 2026) and arriving — as usual on this blog — at the operational patterns we see applied across our DIF clients.
The starting numbers: 1.5% is not just a statistic
The Polimi Contract Logistics Healthcare Observatory 2025 — the reference source for Italian sector data — photographs 2024 with these parameters:
- Italian DIF aggregated revenue: €16.5 billion (significantly growing)
- Segment average EBITDA: 1.5%
- 47% of intermediate distributors below 2% EBITDA
- +9% shipments in 2025 (over 8.5 million)
- +19% kilograms transported, but parcels per shipment declining
- AI adoption: over 50% of client companies, ~60% of logistics service providers
For comparative context: total Italian contract logistics is at 5.3% EBITDA, regional carriers at 4.7%, national carriers at 5.8%. DIF is the lowest segment on the scale. The difference is not anomaly of one year: it’s a structural gap repeating with very similar values for at least five years.
Why Italian DIF is structurally below average
Three forces concur to compress sector profitability, and none of the three is solvable from within with operational discipline alone.
1. Regulated margin — fifteen years of compression
Italian pharmaceutical wholesalers’ margin is fixed by law, not contractually negotiated. It’s an Italian specificity with few parallels in Europe. With article 11 paragraph 6 of Decree-Law 78/2010 (Law 122/2010), the margin was brought from 6.65% to 3% of the public price net of VAT. The 2025 Italian Budget Law added a 0.65% additional margin “non-contestable and non-transferable” bringing the total to 3.65% — but the TAR Lazio ruling of 9 February 2026 excluded generic drugs from the addition, reducing the Budget Law’s actual impact by approximately €20 million per year.
On such a margin structure, every operational inefficiency becomes visible disproportionately: at equal revenue, an additional percentage point of fuel cost or labour cost produces a significantly wider EBITDA effect compared to a sector with contractually higher margins.
2. Direct distribution — the Italian anomaly
A growing share of NHS pharmaceutical value in Italy bypasses intermediate distribution: direct distribution (DD, manufacturer → local health authority/hospital) and distribution on behalf of NHS (DPC — Distribuzione Per Conto, local health authority purchases, pharmacy distributes, wholesaler only does logistics with reduced margin, typically €1-3 per pack). The Italian DD/DPC share on total pharmaceutical value is about 30%, against an EU average around 5% — a system anomaly with few European parallels.
ADF, the Italian Pharmaceutical Distributors Association (35 companies representing over 60% of wholesale revenue and serving 19,000 pharmacies with an average 3-hour order-to-delivery), recurrently defines it in its press releases as “Italy’s European anomaly”. For the intermediate distributor, the effect is twofold: a growing share of value exits the wholesale chain, and what stays in the chain is predominantly drugs at full regulated margin — therefore more sensitive to all other structural pressures.
3. Pharmacy chain disintermediation
The third erosion vector is pharmacy retail consolidation. Capitalised chains — Hippocrates Holding (Antin-owned), Dr.Max (Penta Investments group), LloydsFarmacia (historically McKesson/Walgreens, today evolving) — are acquiring pharmacies at a sustained pace and tend to build proprietary distribution centres for the most profitable flows, leaving DIF with only stockouts, urgencies, controlled substances.
Cooperative consolidation has also accelerated: the birth of QFarma in 2025 — newco controlled 51% by CEF and 49% by the former UNICO cooperatives, with €2.5 billion aggregated revenue, 20 branches, 12,000 pharmacies served and 2,000 employees — consolidated a cooperative pole that exerts direct competitive pressure on regional independent distributors left alone on the territory.
The real killer is not just margin: working capital
On regulated margin and DD/DPC erosion, wholesalers have limited tools. There is however a P&L component that often weighs more than the percentage margin and is instead at least partially under management control: working capital.
The typical Italian intermediate distributor operates with:
- DSO (Days Sales Outstanding): 60-120 days from pharmacies. Major pharmacies, chains and local health authorities pay in the high range; rural independents in the medium range.
- DPO (Days Payables Outstanding): 30-60 days to pharmaceutical manufacturers, with constant pressure to shorten in exchange for commercial discounts.
- DIO (Days Inventory Outstanding): 25-45 days of average inventory (variable by product line; higher for low-rotation lines, lower for blockbusters).
The resulting net working capital cycle is typically 70-110 days: the distributor has to finance for about two-three months the value of drugs sold before cashing them in. On €25 million of annual revenue, that’s €4.5-7 million of working capital tied up at any moment.
At the current cost of money (5-6% for operational bank facilities in Italy), this working capital costs €225-420 thousand per year just in financial interest. On an average EBITDA of 1.5% × €25 million = €375 thousand, it means working capital cost can exceed 60% of the EBITDA itself. The distributor works first of all to pay the bank, not to generate net cash.
Those who default in DIF are rarely the ones with the worst percentage margin. They are often the ones with the worst DSO: a pharmacy or local health authority cluster paying at 150 days instead of 90 can stress the liquidity of a wholesaler for whom the same client would be manageable on margin. It’s the less-told dimension of the sector crisis.
What 1.5% EBITDA looks like on a typical wholesaler
To give concreteness to the number, take a medium-sized regional intermediate distributor: €25 million annual revenue, of which €17.5 million branded NHS and €7.5 million generics NHS (typical 70/30 mix). 200-250 pharmacies served, geographic area one or two regions, fleet of 20 light refrigerated vehicles.
Annual revenue: €25,000,000
Cost of goods sold (drug purchase): ~€21,500,000 (86%)
Gross margin: €3,500,000 (14%) — almost all on regulated 3.65% or 3%
Direct operating costs:
- Personnel (warehouse + drivers + dispatcher + admin): €1,700,000
- Fleet fuel: €300,000
- Vehicle depreciation and leasing: €350,000
- Depot rent + utilities: €380,000
- Maintenance + insurance + vehicle tax: €230,000
- Supplier qualification, GDP, FMD, AIFA audit costs: €90,000
- IT, management systems, telematics: €75,000
Total operating costs: ~€3,125,000
EBITDA = Gross margin - Operating costs = €375,000
EBITDA / Revenue = 1.5%Now add the items below the EBITDA line:
- Financial interest (working capital + medium/long-term financing): €280,000
- Asset depreciation: €60,000
EBIT: €35,000
EBT (pre-tax): €35,000
Taxes (~28%): €10,000
Net income: ~€25,000
Net income / Revenue: 0.1%Net margin on €25 million of revenue is therefore in the €25-50 thousand range. It’s the difference between being in profit and being at a loss. A single adverse variation — an important customer paying late, fuel inflation not recoverable, an AIFA audit with non-conformities requiring investments, an accident with the newest van — can shift the financial year result below zero.
For a sector that performs an essential public service (NHS drug distribution within 12 working hours per Italian decree 219/2006), sustainability is structurally precariously balanced.
Operational levers: what can be done without waiting for new laws
The macro framing is important, but doesn’t solve. Four concrete operational levers an intermediate distributor can pull without depending on new regulatory interventions.
Lever 1 — Pharmacy-by-pharmacy cost-to-serve
The most immediate lever, and the one we work on directly with our DIF clients, is measuring pharmacy-by-pharmacy cost-to-serve. On an average EBITDA of 1.5%, recovering even just 0.2-0.5% of revenue through targeted decisions on structurally loss-making pharmacies means taking EBITDA from €375,000 to €425-500,000 — a 15-35% improvement in operating result at equal revenue.
The operational decisions are four: reduce frequency, increase basket with value-added services, recompose geographic clusters, renegotiate conditions (logistics contribution, minimum frequency, minimum basket). They are micro-decisions that sum up across dozens of marginal pharmacies. The Margin Calculator is the typical starting point in initial calls with wholesalers who want to look at the problem with numbers.
Lever 2 — Progressive fixed-route recomposition
The second lever is monthly fixed-route optimisation. On an annual basis, an intermediate distribution with routes not re-optimised for 12+ months typically recovers 5-10% of kilometres at equal service by applying a progressive recomposition (the 2-3 clusters with greatest drift each quarter) instead of a destabilising complete redesign. On a fleet of 20 vehicles with average consumption and diesel above €2/L, that’s €60-90 thousand per year of fuel savings. The pattern is described in the pillar on pharmaceutical logistics.
Lever 3 — Specialisation on less-regulated segments
The third lever is strategic: shift the mix toward segments where margin is not fixed by law but negotiated. Four directions seen on the market:
- Veterinary: Italian veterinary drug market ~€700 million, in stable growth, margins 8-15%.
- Parapharmacy, dermocosmetics, nutraceuticals: margins 8-15%, market growing 4-6% annually.
- Premium cold chain: management of specialty lines at -20°C (biologics, some oncologicals, some vaccines) as entry barrier and margin lever.
- Value-added services for the pharmacy: pre-orders, fast shuttle, returns management, IT/marketing support in white label — additional contractual packages.
None of these is a shortcut: it requires investments, process redesign, staff training. But it’s the only strategic direction to exit the compression of the regulated 3.65% (or 3%).
Lever 4 — Working capital discipline
The fourth lever is the hardest to implement but the one with the most immediate cash impact: shortening DSO. It means systematising credit management (customer rating, differentiated conditions, guarantees on high-risk clusters), assigning to factoring or invoice advance the at-risk receivables, and — more radically — repricing contracts with structurally late customers, recognising that a customer at 150 days of DSO is effectively a reduced-margin customer.
On €25 million revenue, dropping by 15 days of average DSO frees about €1 million of tied-up liquidity: at 5% cost of money, that’s €50,000 of interest saved per year. On €375,000 of EBITDA, it’s a +13% EBITDA “all cash, zero additional revenue”.
Frequently asked questions
Is the 1.5% EBITDA of Italian DIF a cyclical or structural number?
Structural. The Polimi Observatory tracks the segment over several years and the value oscillates in the 0.5-2% range for at least five years, without significant improvements. The 2025 Italian Budget Law + 0.65% additional margin could have changed the picture, but the TAR Lazio ruling of 9 February 2026 reduced the actual effect on distribution revenue.
Why is wholesale margin regulated by law in Italy?
For historical reasons tied to the NHS model: the drug reimbursed by the national health system has an institutionally fixed public price, and within that price the share of the three actors (industry, distributor, pharmacy) is established by law. It’s an Italian specificity with few parallels in Europe, where wholesale margin is typically contractually negotiated.
How is the 47% of distributors below 2% EBITDA distributed by size?
Mid-sized regional independent wholesalers (€10-30 million annual revenue) tend to concentrate in that zone, while large national players (Comifar, QFarma) and specialised distributors generally have slightly higher EBITDA. The critical size for sustainability is well above the average — the consolidation of the sector (the ~60 Italian wholesalers have halved in the last 20 years) reflects exactly this pressure.
How many EBITDA points can a more efficient fleet recover?
On sector benchmarks, a serious programme of route optimisation + cost-to-serve + KPI discipline can lead to a recovery of 0.5-1.5 percentage points of EBITDA on the medium term (24-36 months). From a starting point of 1.5%, it’s +30-100% EBITDA. It doesn’t solve the sector’s structure, but repositions the operator from the red zone to the sustainability zone.
In summary
Italian pharmaceutical intermediate distribution is the contract logistics segment with the worst profitability: 1.5% average EBITDA, 47% of operators below 2%. The reasons are structural and multi-level: margin regulated by Law 122/2010 and partially reintegrated by the 2025 Italian Budget Law (with the 2026 TAR complication on generics), DD/DPC erosion with Italian share at 30% versus 5% EU, pharmacy chain disintermediation with proprietary distribution centres.
The real sector killer — less told than the regulated margin but equally heavy — is working capital: the 70-110 day cycle means €4.5-7 million of tied-up capital for every €25 million of revenue, with an annual financial cost that can absorb more than 60% of EBITDA itself.
On structural pressures, distributors have limited tools. On four operational levers — pharmacy-by-pharmacy cost-to-serve, progressive route recomposition, specialisation on less-regulated segments, DSO discipline — there is room to intervene and it is quantifiable: a recovery of 0.5-1.5 percentage points of EBITDA in 24-36 months is realistically within reach of a wholesaler with execution discipline.
If you want to understand where to start on your P&L — where the most recoverable lost margin sits, which operational decisions produce the biggest impact with least disruption — talk to our team. Three months of POD, telematics and product mix data are enough to build a concrete margin recovery projection on your specific profile.